Thr70
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr70  -  4E-BP1 (human)

Site Information
rNsPVtktPPRDLPt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447528

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 69 ) , [32P] bio-synthetic labeling ( 68 ) , electrophoretic mobility shift ( 63 , 67 , 71 ) , flow cytometry ( 11 ) , immunoprecipitation ( 2 , 11 ) , mass spectrometry ( 3 , 6 , 8 , 9 , 11 , 12 , 13 , 16 , 17 , 18 , 21 , 22 , 24 , 25 , 27 , 28 , 29 , 30 , 32 , 34 , 35 , 36 , 37 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 52 , 54 , 57 , 58 , 68 , 72 ) , mutation of modification site ( 4 , 15 , 68 , 69 , 71 ) , phospho-antibody ( 2 , 4 , 5 , 14 , 19 , 20 , 23 , 33 , 38 , 39 , 53 , 55 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ) , phosphopeptide mapping ( 68 , 69 ) , western blotting ( 2 , 4 , 5 , 14 , 19 , 20 , 23 , 33 , 38 , 39 , 53 , 55 , 60 , 62 , 64 , 65 , 66 , 67 , 68 , 69 )
Disease tissue studied:
bone cancer ( 66 ) , brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 ) , breast cancer ( 8 , 17 , 18 , 20 , 29 , 33 , 60 ) , breast ductal carcinoma ( 17 ) , HER2 positive breast cancer ( 6 ) , luminal A breast cancer ( 6 ) , luminal B breast cancer ( 6 ) , breast cancer, surrounding tissue ( 6 ) , breast cancer, triple negative ( 6 , 17 , 20 ) , cervical cancer ( 40 ) , cervical adenocarcinoma ( 40 ) , kidney cancer ( 5 ) , leukemia ( 32 , 38 , 50 , 55 , 60 ) , acute myelogenous leukemia ( 32 , 60 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 28 ) , acute megakaryoblastic leukemia (M7) ( 28 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 28 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 28 ) , acute myeloblastic leukemia, without maturation (M1) ( 28 ) , chronic myelogenous leukemia ( 38 , 50 , 55 ) , liver cancer ( 19 ) , lung cancer ( 24 , 29 , 34 , 44 ) , non-small cell lung cancer ( 29 , 44 ) , non-small cell lung adenocarcinoma ( 24 , 34 ) , lymphoma ( 39 ) , anaplastic large cell lymphoma ( 39 ) , B cell lymphoma ( 28 ) , non-Hodgkin's lymphoma ( 28 ) , T cell lymphoma ( 39 ) , ovarian cancer ( 17 ) , multiple myeloma ( 28 ) , melanoma skin cancer ( 13 ) , rhabdomyosarcoma ( 14 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection] ( 37 ) , 293 (epithelial) ( 4 , 11 , 23 , 62 , 64 , 65 , 67 , 68 , 71 ) , 293E (epithelial) ( 66 ) , 786-O (renal) [VHL (human), transfection] ( 9 ) , 786-O (renal) ( 9 ) , A431 (epithelial) ( 72 ) , ACHN (renal) ( 5 ) , AML-193 (monocyte) ( 28 ) , BaF3 ('B lymphocyte, precursor') ( 38 ) , blood ( 19 ) , breast ( 6 , 17 ) , BT-20 (breast cell) ( 29 ) , BT-474 (breast cell) ( 8 ) , BT-549 (breast cell) ( 29 ) , BV-173 (myeloid) ( 38 , 55 ) , Calu 6 (pulmonary) ( 29 ) , CMK (megakaryoblast) ( 28 ) , CTS (myeloid) ( 28 ) , DOHH2 ('B lymphocyte, precursor') ( 28 ) , DU 145 (prostate cell) ( 70 ) , E.coli (bacterial) ( 11 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 30 ) , Flp-In T-Rex-293 (epithelial) ( 30 ) , H2009 (pulmonary) ( 29 ) , H2077 (pulmonary) ( 29 ) , H2887 (pulmonary) ( 29 ) , H322M (pulmonary) ( 29 ) , HCC1359 (pulmonary) ( 29 ) , HCC1806 (breast cell) ( 20 ) , HCC1937 (breast cell) ( 29 ) , HCC2279 (pulmonary) ( 29 ) , HCC4006 (pulmonary) ( 29 ) , HCC827 (pulmonary) ( 29 ) , HEK293T (epithelial) ( 12 , 54 ) , HEL (erythroid) ( 28 ) , HeLa (cervical) ( 3 , 4 , 14 , 16 , 27 , 36 , 41 , 45 , 46 , 47 , 48 , 49 , 52 , 69 ) , HeLa S3 (cervical) ( 40 ) , HepG2 (hepatic) ( 19 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 18 ) , HMLER ('stem, breast cancer') ( 18 ) , HOP62 (pulmonary) ( 29 ) , HUES-7 ('stem, embryonic') ( 43 ) , HUES-9 ('stem, embryonic') ( 35 ) , Jurkat (T lymphocyte) ( 25 ) , K562 (erythroid) ( 27 , 38 , 41 , 50 , 55 ) , Karpas-299 (T lymphocyte) ( 39 ) , Kasumi-1 (myeloid) ( 28 ) , KG-1 (myeloid) ( 28 , 32 ) , LCLC-103H (pulmonary) ( 29 ) , liver ( 22 ) , lung ( 24 ) , MCF-7 (breast cell) ( 8 , 29 , 33 , 60 ) , MDA-MB-231 (breast cell) ( 29 , 33 ) , MDA-MB-468 (breast cell) ( 29 ) , MV4-11 (macrophage) ( 28 ) , myeloid-bone marrow ( 53 ) , NB-4 (myeloid) ( 60 , 61 ) , NCI-H1299 (pulmonary) ( 44 ) , NCI-H1395 (pulmonary) ( 29 ) , NCI-H1568 (pulmonary) ( 29 ) , NCI-H157 (pulmonary) ( 29 ) , NCI-H1648 (pulmonary) ( 29 ) , NCI-H1666 (pulmonary) ( 29 ) , NCI-H1703 (squamous) ( 57 , 58 ) , NCI-H2030 (pulmonary) ( 29 ) , NCI-H2172 (pulmonary) ( 29 ) , NCI-H322 (pulmonary) ( 29 ) , NCI-H520 (squamous) ( 29 ) , NCI-H647 (pulmonary) ( 29 ) , OPM-2 (plasma cell) ( 28 ) , ovary ( 17 ) , P31/FUJ (erythroid) ( 28 ) , PC3 (prostate cell) ( 70 ) , PC9 (pulmonary) ( 29 ) , Rh18 (muscle cell) ( 70 ) , Rh30 ('muscle, skeletal') ( 14 , 70 ) , RL ('B lymphocyte, precursor') ( 28 ) , RPMI-8266 (plasma cell) ( 28 ) , SF767 (glial) ( 2 ) , SH-SY5Y (neural crest) ( 21 ) , SR (T lymphocyte) ( 39 ) , SU-DHL-6 (B lymphocyte) ( 28 ) , SU-DHL1 (T lymphocyte) ( 39 ) , U-118MG (glial) ( 2 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 34 ) , U-1810 (pulmonary) ( 34 ) , U-251 MG (glial) ( 2 ) , U266 (plasma cell) ( 28 , 63 ) , U2OS (bone cell) [GR (human)] ( 66 ) , U87MG (glial) ( 2 ) , WM239A (melanocyte) ( 13 )

Upstream Regulation
Regulatory protein:
4E-BP1 (human) ( 51 ) , GSK3A (human) ( 20 ) , LYN (human) ( 53 ) , mTOR (human) ( 14 , 39 ) , PLK1 (human) ( 59 ) , PRAS40 iso3 (human) ( 51 ) , Raptor (human) ( 14 ) , RICTOR (human) ( 14 ) , TSC1 (human) ( 59 ) , TSC2 (human) ( 59 )
Putative in vivo kinases:
mTOR (human) ( 65 , 71 )
Kinases, in vitro:
CDK1 (human) ( 69 ) , Cot (human) ( 42 ) , ERK2 (human) ( 71 ) , GSK3B (human) ( 5 ) , mTOR (human) ( 71 )
Putative upstream phosphatases:
PPM1G (human) ( 2 )
Treatments:
1-azakenpaullone ( 20 ) , AG1296 ( 53 ) , AG490 ( 53 ) , amino_acids ( 51 , 71 ) , AR-A014418 ( 5 , 20 ) , As2O3 ( 55 ) , bisindolylmaleimide ( 67 ) , dasatinib ( 41 ) , EGF ( 3 ) , estradiol ( 56 ) , fetal growth restriction ( 19 ) , IFN-beta ( 63 ) , IFN-gamma ( 61 ) , IGF-1 ( 14 ) , imatinib ( 38 ) , insulin ( 51 , 62 , 66 , 67 , 71 ) , LRRK2-IN-1 ( 21 ) , LY294002 ( 2 , 55 , 60 , 63 ) , MK-2206 ( 2 ) , nocodazole ( 40 ) , OSI-027 ( 38 ) , PD184352 ( 67 ) , PD98059 ( 67 ) , phorbol_ester ( 51 , 67 ) , PP2 ( 53 ) , PP242 ( 14 ) , rapamycin ( 2 , 5 , 20 , 33 , 38 , 53 , 55 , 60 , 62 , 63 , 66 , 67 , 68 , 70 , 71 ) , retinoic_acid ( 60 ) , serum ( 68 ) , siRNA ( 53 , 59 ) , U0126 ( 67 )

Downstream Regulation
Effects of modification on 4E-BP1:
activity, inhibited ( 61 ) , molecular association, regulation ( 11 , 15 , 61 , 69 , 70 ) , phosphorylation ( 23 , 64 ) , protein conformation ( 11 )
Effects of modification on biological processes:
cell cycle regulation ( 11 ) , transcription, altered ( 11 ) , translation, altered ( 69 ) , translation, induced ( 2 ) , translation, inhibited ( 15 )
Inhibit interaction with:
4E-BP1 (human) ( 11 ) , EIF4E (human) ( 15 , 61 , 69 , 70 )

Disease / Diagnostics Relevance
Relevant diseases:
acute myelogenous leukemia ( 53 )

References 

1

Wang C, et al. (2019) Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268-272
31578521   Curated Info

2

Xu K, et al. (2016) Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase. Oncogene 35, 5807-5816
27065332   Curated Info

3

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

4

Velásquez C, et al. (2016) Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation. Proc Natl Acad Sci U S A 113, 8466-71
27402756   Curated Info

5

Ito H, et al. (2016) GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. BMC Cancer 16, 393
27387559   Curated Info

6

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

7

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

8

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

9

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

10

Agarwal S, Bell CM, Rothbart SB, Moran RG (2015) AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. J Biol Chem 290, 27473-86
26391395   Curated Info

11

Sekiyama N, et al. (2015) Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc Natl Acad Sci U S A 112, E4036-45
26170285   Curated Info

12

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

13

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

14

Chen L, et al. (2015) Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget 6, 7136-50
25762619   Curated Info

15

Peter D, et al. (2015) Molecular Architecture of 4E-BP Translational Inhibitors Bound to eIF4E. Mol Cell 57, 1074-87
25702871   Curated Info

16

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

17

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

18

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

19

Abu Shehab M, et al. (2014) Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction. Endocrinology 155, 1327-39
24437487   Curated Info

20

Shin S, et al. (2014) Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 33, 1690-9
23584478   Curated Info

21

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

22

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

23

Shin S, Wolgamott L, Roux PP, Yoon SO (2014) Casein kinase 1ε promotes cell proliferation by regulating mRNA translation. Cancer Res 74, 201-11
24247720   Curated Info

24

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

25

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

26

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

27

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

28

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

29

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

30

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

31

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

32

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

33

Yellen P, et al. (2011) High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10, 3948-56
22071574   Curated Info

34

Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78
21413766   Curated Info

35

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

36

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

37

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

38

Carayol N, et al. (2010) Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 107, 12469-74
20616057   Curated Info

39

Anastasov N, et al. (2010) C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 95, 760-7
20015877   Curated Info

40

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

41

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

42

Wu B, Jiang P, Mu Y, Wilmouth RC (2009) Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210. Biol Chem 390, 1271-7
19804365   Curated Info

43

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

44

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

45

Moritz A (2008) CST Curation Set: 5062; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

46

Moritz A (2008) CST Curation Set: 5063; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

47

Moritz A (2008) CST Curation Set: 5072; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

48

Moritz A (2008) CST Curation Set: 5073; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

49

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

50

Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Fonseca BD, Lee VH, Proud CG (2008) The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK. Biochem J 411, 141-9
18215133   Curated Info

52

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

53

Dos Santos C, et al. (2008) A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269-79
18056483   Curated Info

54

Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204
17287340   Curated Info

55

Yoon P, et al. (2006) Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol Cancer Ther 5, 2815-23
17121928   Curated Info

56

Yu J, Henske EP (2006) Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Cancer Res 66, 9461-6
17018601   Curated Info

57

Possemato A (2006) CST Curation Set: 1608; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

58

Possemato A (2006) CST Curation Set: 1570; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

59

Astrinidis A, Senapedis W, Henske EP (2006) Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Hum Mol Genet 15, 287-97
16339216   Curated Info

60

Lal L, et al. (2005) Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 105, 1669-77
15471950   Curated Info

61

Lekmine F, et al. (2004) Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res 295, 173-82
15051500   Curated Info

62

Beugnet A, Wang X, Proud CG (2003) Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem 278, 40717-22
12912989   Curated Info

63

Lekmine F, et al. (2003) Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem 278, 27772-80
12759354   Curated Info

64

Wang X, et al. (2003) The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol 23, 1546-57
12588975   Curated Info

65

McMahon LP, et al. (2002) The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol 22, 7428-38
12370290   Curated Info

66

Tee AR, et al. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99, 13571-6
12271141   Curated Info

67

Herbert TP, Tee AR, Proud CG (2002) The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 277, 11591-6
11799119   Curated Info

68

Gingras AC, et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15, 2852-64
11691836   Curated Info

69

Heesom KJ, Gampel A, Mellor H, Denton RM (2001) Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol 11, 1374-9
11553333   Curated Info

70

Dudkin L, et al. (2001) Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7, 1758-64
11410517   Curated Info

71

Mothe-Satney I, et al. (2000) Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 275, 33836-43
10942774   Curated Info

72

MS This site is one of 509 sites observed by D. Stover et al using MS/FTMS of peptides from lysates of A431 cells grown either in vitro or as xenografts in BALB/c nu/nu mice. These sites were previously unpublished until now (July 27 2006). 66 sites were previously published in: Stover DR, et al. Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts Clin Proteomics 2004 Mar 01; 1(1): 69-80.
Curated Info